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ABSTRACT
Gastrointestinal infections are one of the most frequent medical conditions diagnosed in patients who 
travel to tropical or subtropical destinations. The most common disorder occurring in up to 60% travelling 
people is travelers’ diarrhea (TD). The illness is defined as a minimum of three loose stools within 24 ho-
urs; in most cases TD is caused by the enterotoxigenic escherichia coli. Its symptoms usually persist for  
4–5 days and resolve spontaneously or on self-administered empirical antimicrobial therapy, but in case 
of an invasive infection, it is necessary to seek medical care. As most tourists travel for 1–2 weeks, the 
disease often persists or develops upon return; therefore, it is important to raise awareness of TD’s clinical 
features and treatment options among physicians from travelers’ home countries unaccustomed to this 
health problem. Another issue, which is gaining more and more importance in recent years, is post-infectious 
irritable bowel syndrome, a chronic disturbance affecting up to 17% of patients, who have had travelers’ 
diarrhea. This review aims to promote prophylaxis of gastrointestinal disorders and to extend knowledge 
about their after-effects in returned travelers. 
(Int Marit Health 2019; 70, 4: 244–251)
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INTRODUCTION
Gastrointestinal (GI) infections are one of the most 
frequent health problems among people travelling to low 
income countries [1, 2], which may greatly affect tourists’ 
holiday or business plans [3]. among the etiological factors 
bacteria were found to be the most common, but viruses 
and parasites may also be responsible for GI infections. 
The risk factors commonly associated with GI infections 
include lack of compliance with hygiene practices, drinking 
tap water or eating food of unknown origin [4]. Travelers’ 
diarrhea (TD) is by far the most common GI infection among 
travelling people [4, 5]. Its symptoms usually appear within 
the first 1–2 weeks of travel; in 10% of patients can persist 
more than a week [1], although the median duration is 
2 days [6]. as exotic destinations are becoming increasingly 
popular among tourists, physicians working in developed 
countries are now more likely to see patients presenting 
with a travel-related health problem which persists or de-
velops upon return.
EPIDEMIOLOGY
about half a billion people from developed countries 
travel internationally each year, of whom as many as 
100 million travel to a developing regions of the world [4]. 
among the latter, 60% will develop diarrhea [7], and 
8% will seek medical help during or shortly after travel. 
The age groups that are most likely to be affected by 
GI disorders include children (younger than 2 years 
old) and young adults [4]. The most common GI infec-
tion, i.e. TD [4, 5], occurs in 20% to 50% of travelers 
[6] (the indexes depending on a source), or 11 million 
of travelling people annually [3]. a total of 17% of pa-
tients return home with clinical manifestations of the 
disease, and 2% develop symptoms after their return 
[6]. GI infections are a common problem which requires 
pre-travel advice. It is worth noting that in the last 
20 years the number of TD cases during a 2-week trip 
has decreased remarkably, from 65% to 10–40% de-
pending on the destination (Fig. 1) [8].
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RISK FACTORS 
Most cases of GI infections are transmitted through the 
fecal-oral route [9]. For this reason, most, if not all, risk 
factors are related to hygiene and eating habits. The major 
risk factors can be broadly divided into two categories: 
environmental and host hazards. The most important of 
the environmental hazards is the travel destination. The 
highest risk for GI infections is reported from developing 
countries, which is due to poor standards of sanitation and 
hygiene [3, 4, 9, 10]. The income level is inversely propor-
tional to GI incidence rates [7]. according to the results of 
a retrospective observational analysis of 6,086 travelers 
by an international association of travel medicine clinics, 
travel to Sub-Saharan africa, South america and South 
asia is associated with the highest risk of GI infection, with 
India and Nepal having the highest risk of all countries ana-
lysed in the study. This applies to all pathogens responsible 
for GI infections (bacteria, parasites, and viruses) [7]. No 
geographical association has been found for persistent 
diarrhea [10]. In some regions, such as Northeast asia and 
Northern Mediterranean the risk has lowered compared to 
a study performed in 1986, possibly by the improvement of 
tourism infrastructure [4, 7]. another risk factor is related 
to the style of travelling. In general, backpacking is said to 
present a high risk for GI disorders, most likely due to more 
risky behaviour, such as drinking tap water and eating street 
food [4]; however, luxury all-inclusive hotels and cruises are 
not always safer than cheap hostels, because of serving 
food stored for a long-term [3, 11]. also, eating in private 
homes is safer than eating in restaurants [3]. Some foods 
and beverages are especially risky, e.g. shellfish, which 
accumulates many pathogens within (Vibrio cholerae, Noro-
virus, Hav) [4] and drinks with ice cubes, which are usually 
prepared from tap water (may be contaminated with fecal 
bacteria) [3]. Travelers need to keep in mind that contact 
with local animals can result in a Campylobacter or Giardia 
infection. another issue to consider is the length of travel 
and stay. Normally, the longer the trip, the higher the risk 
of a GI infection [6]. a minimum of 2-week stay in South 
or Southeast asia, Middle east and South america holds 
the highest risk of acquiring a GI disorder [4]. as for the 
host hazards, the most relevant is the age of a traveller. 
Teenagers and young adults are in the highest risk group 
[6, 7, 11], and children are the ones who are the most often 
hospitalised [11]. There is no difference between sexes as 
to the risk of acquiring a GI infection [6, 11]. People with 
hypochlorhydria and patients treated with antacids are 
more likely to fall ill [11, 12] as higher level of gastric acid 
would have had bactericidal effect. Some genetic features, 
although rarely assessed [11], give an interesting insight 
into travel infections — people with blood group 0 or with 
mutation in interleukin (Il)-8 [3, 4], lactoferrin or Il-10 [4] 
gene, are prone to TD [3]. Immunocompromised patients 
are also more likely to acquire a GI illness during travel, 
and are more often diagnosed with protozoan infections 
[3], which may lead to persistent diarrhea.
TRAVELERS’ DIARRHEA
Travelers’ diarrhea is defined as 3 or more stools per 
day, sometimes with additional symptoms, such as ab-
dominal cramps, tenesmus, nausea, vomiting, fever, chills 
or prostration, all starting during or shortly after travel. In 
5–15% cases of diarrhea blood or mucus may occur in 
stools (dysentery) [13]. The world Health Organization adds 
the number of stools greater than normal for a relevant 
individual to the definition [11]. TD occurs as a result of 
Figure 1. Incidence rates of travelers’ diarrhea in the initial 2 weeks of stay in various regions of the world among visitors residing in indu-
strialized countries, 1996–2008. Source: Steffen r, Hill Dr, DuPont Hl. Traveler’s diarrhea: a clinical review. JaMa 2015; 313: 71–80 [8]
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exposure to local enteric pathogens during international 
relocation.
Etiology. The pathogen causing TD is identified in only 
40–60% of travelers with symptoms. The identification 
of the pathogen is not always needed, considering the 
symptoms are usually either self-limiting or disappear rap-
idly after empirical self-administered therapy [3]. However, 
when diagnosed, the predominant pathogen worldwide is 
the enterotoxigenic Escherichia coli (eTeC) [2, 4, 12, 14] 
(Table 1). eTeC has been identified in 33.6% of patients 
suffering from TD in South america, 31.2% in africa and 
30.1% in South asia. according to different sources, from 
50 to 85% cases of TD are caused by bacteria [2, 3], where-
as 10–15% of cases are caused by viruses, mostly in africa 
and South america [15]. Parasites are estimated to cause 
17% of TD cases, and are often identified in patients with 
persistent diarrhea [3]. However, even 34–41% cases are 
caused by a mixed infection, the frequent co-pathogens 
being eTeC and eaeC (enteroaggregative E. coli) [4]. eTeC, 
eaeC, Campylobacter, Salmonella, Shigella and Vibrio spp. 
are the most common bacteria found in patients with TD 
[2, 4, 16]. Others have specific geographical distribution, 
e.g. Aeromonas spp. and Plesiomonas shigelloides are 
often found in asia [3] while Campylobacter spp. has been 
the most identified pathogen in travelers to Southeast asia 
(32%), which is important to remember when adjusting the 
treatment, as there is a high resistance of these strains to 
commonly used ciprofloxacin [4]. viruses, especially the 
norovirus species, are often connected with outbreaks of 
the illness in small travel communities such as passengers 
of a cruise ship [3, 17]. rotavirus infection is a common 
diarrhea cause in travelers to Mexico [2]. Giardia intestinalis 
and Entamoeba histolytica are the most common protozoa 
causing TD, although E. histolytica is thought to be overdi-
agnosed as it is indistinguishable microscopically from its 
harmless cousin E. dispar. Giardia, Cyclospora and Crypto-
sporidium parvum are often identified in returned travelers 
with persistent diarrhea [9, 18, 19]. russia and Nepal are 
locations where parasites are commonly identified among 
travelers with diarrhea [2].
Some cases of acute diarrhea with short incubation 
period may be a consequence of consuming toxins which 
have already been released by bacteria, mostly in food 
which has not been stored properly. The most common 
toxin-producing bacteria include Clostridium perfringens, 
Staphylococcus aureus, Bacillus cereus and Clostridium 
botulinum. The most threatening infections are by C. per-
fringens type C (they may lead to necrosis of the intestine 
wall) and by C. botulinum (with subsequent injury of the 
nervous system) [2]. a non-infectious cause of TD is cigua-
toxin which accumulates in big reef fish in the Pacific and 
the Caribbean area. It causes acute diarrhea followed by 
neurological symptoms [20].
Clinical course. according to the statistics, the onset 
of symptoms occurs most frequently either on the first 
3–4 days abroad or on the 10th day of the trip (Table 2). 
The untreated TD lasts 4 days [4], while half of the patients 
recover even faster — within 48 hours. The mean duration 
of patient’s incapacity is less than 1 day [8]. TD has a wide 
range of course paths, from self-limiting indisposition to 
a serious condition with a need of hospitalisation. In 1% 
of cases TD evolves from an acute distress to a chronic 
disease and sometimes it may have long-term consequenc-
es on the overall health of the patient [4, 11] causing, 
among others, post-infectious irritable bowel syndrome 
(PI-IBS) [8]. In most cases the clinical course is mild and 
diarrhea consists of no more than 5 stools per day, while 
accompanying symptoms are nothing more but nausea and 
abdominal pain [4]. 1% of patients require hospitalisation. 
General practitioners who encounter patients with diarrhea 
returning from a travel should be aware of the impact this 
Table 1. Distribution of pathogens in acute cases of travelers’ 
diarrhea by geographical region
Pathogen Latin  
America (%)
Asia 
(%)
Africa 
(%)
Middle 
East (%)
enterotoxigenic 
E. coli
17–70 6–37 8–42 29–33
enteroinvasive 
E. coli
2–7 2–3 0–2 1
Other E. coli  
(ePeC, eaeC, eHeC)
5–15 1 2–7 Na
Shigella spp. 2–30 0–17 0–9 8–26
Salmonella spp. 1–16 1–33 4–25 2
Campylobacter 
jejuni
1–5 9–39 1–28 1–2
Aeromonas spp. 1–5 1–57 0–9 1
Plesiomonas  
shigelloides
0–6 3–13 3–5 1
Vibrio cholerae 
non-01
0–2 1–7 0–4 2
Yersinia spp. Na 0–3 Na 1
Rotavirus spp. 0–6 1–8 0–36 Na
Entamoeba  
histolytica
Na 5–11 2–9 Na
Giardia intestinalis 1-2 1-12 0-1 Na
Cryptosporidium 
spp.
Na 1–5 2 Na
No pathogen  
identified
24–62 10–56 15–53 50–51
Na — not available; Source: Castelli F, Pezzoli C, Tomasoni l. epidemiology  
of travelers’ diarrhea. J Travel Med. 2001; 8(Suppl. 2): S26–S30 [19]
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Table 2. etiology and clinical symptoms of gastrointestinal disorders in returned travelers
Etiology Incubation period Symptoms Duration of symptoms
Campylobacter jejuni 2–5 days Fever, abdominal pain, vomiting, diarrhea 2–10 days
Clostridium difficile 5 days – 5 months Fever, abdominal pain, diarrhea 4 days – weeks
Escherichia coli O157:H7 1–8 days abdominal pain, vomiting, acute diarrhea  
often with blood
5–10 days
enterotoxigenic Escherichia coli (eTeC) 1–3 days abdominal pain, watery diarrhea 3–7 days
Salmonella enteritidis 1–3 days Fever, abdominal pain, vomiting, diarrhea 4–7 days
Shigella spp. 24–48 h Fever, abdominal pain 4–7 days
Vibrio cholerae 24–72 h life threatening dehydration caused by  
watery diarrhea and vomiting
3–7 days
Vibrio parahaemolyticus 2–48 h watery diarrhea, abdominal pain, nausea,  
vomiting
2–5 days
Yersinia enterocolitica 24–48 h Fever, abdominal pain, vomiting, diarrhea  
with blood
1–3 weeks
Norovirus 12–48 h Fever, muscle pain, abdominal pain, nausea, 
vomiting, diarrhea
12–60 h
rotavirus 24–72 h Fever, nausea, vomiting, watery diarrhea 4–10 days
Giardia intestinalis 9–15 days Persistent diarrhea, abdominal pain, bloating, 
weight loss
> 14 days
Entamoeba histolytica 8–30 days Diarrhea with mucus and blood, abdominal 
pain; chronic type of amoebiasis (amoebic liver 
abscess)
> 14 days
Cryptosporidium parvum 3–12 days watery diarrhea, abdominal pain, nausea,  
vomiting, weight loss
> 14 days
Source: Korzeniewski K. Gastrointestinal disorders in returning travellers. FMr 2018; 12(4): 115–126 [4]
disease can have. Diarrhea interferes with absorption of 
some medications — warfarin and other anticonvulsants as 
well as oral contraception. loss of fluids leads to electrolyte 
disorders and is especially dangerous for young children. 
Some pathogens, common especially in Southeast asia, 
such as Shigella, Salmonella and Campylobacter, can lead 
to reiter’s syndrome or trigger an inflammatory disease in 
the intestine. Over 10% of patients with TD develop post-in-
fectious irritable bowel syndrome [3]. 
Pathophysiology. Understanding the pathogenesis of 
TD will suggest the right path of the treatment. Bacteria, 
the main cause of TD, use colonisation factors (such as 
fimbriae and pilli) to colonise the intestine; virulence factors 
like enterotoxins, endotoxins and cytotoxins that cause the 
symptoms as well as some bacteria invade the intestinal 
mucosa themselves [9]. eTeC and Vibrio cholerae release 
enterotoxins in the small intestine. These particles increase 
levels of caMP by deregulating adenylate cyclase, which 
escalates the production of secretory fluid, and, in effect, 
causes watery and abundant diarrhea termed secretory 
diarrhea. This type of diarrhea with acute abdominal pain 
is characteristic for cholera [9, 20]. Other enterotoxins yield 
a similar effect, but through a different path — lipopolysac-
charide endotoxin through cGMP pathway [21], ciguatera 
toxin through calcium-dependent pathway and Shigella 
toxin through nitric oxide pathway. each of them induces 
watery diarrhea. another mechanism of non-inflammato-
ry diarrhea, seen often in persistent diarrhea as well as 
rotavirus infections, uses the law of osmosis. In osmotic 
diarrhea poorly absorbable substance creates osmotic 
pressure across the mucosa of the intestine wall [9]. It is 
easy to fall into dehydration as liquids pass to the lumen of 
the intestine according to the concentration gradient. The 
diarrhea is frothy and exploding and ceases after fasting. 
exudative, inflammatory diarrhea with blood, mucus and 
pus in stool (dysentery) is caused by bacteria that invade 
mucosa and release cytotoxins [4]. They act mostly in the 
distal part of the intestines — distal ileum and colon. Cy-
totoxins kill cells by suppressing the synthesis of proteins 
(shiga toxin produced by Shigella dysenteriae type 1), cre-
ating pores in the cell membrane (hemolysins released by 
Vibrio parahaemolyticus) or ceasing the extension of actin 
filaments. This type of diarrhea is usually accompanied 
by systemic symptoms — fever and a rise of inflammation 
markers in blood [9]. Some bacteria combine various diar-
rheal mechanisms and cause secretory and inflammatory 
diarrhea simultaneously — these are the capacities owned 
by C. jejuni, Salmonella spp. and Aeromonas spp. among 
Int Marit Health 2019; 70, 4: 244–251
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protozoa, E. histolytica causes a severe disease by creat-
ing ulcers on the intestine wall using cytolysis, proteases, 
toxins and phagocytosis. It can also spread to other organs, 
especially the liver, and reside within. Giardia attaches itself 
to the wall of the small intestine, but its virulence factors 
have not been yet discovered [9].
Diagnosis. Diarrhea without the inflammation compo-
nent (fever or blood in stool) lasting less than 5 days usually 
does not require pathogen investigation [9, 10]. Nonetheless, 
we should consider further diagnostics when the symptoms 
are severe, when there was an outbreak of symptoms in one 
group of travelers, when diarrhea is persistent, when the 
patient is immunodeficient or when in differential diagnosis 
we suspect that the patient may suffer from an inflamma-
tory bowel disease. Choosing the right treatment should be 
guided by a thorough interview which, apart from the existing 
symptoms, focuses on the destination of the travel and the 
medical history of the patient. It is also crucial to know the 
incubation period of certain pathogens; generally, symptoms 
that persist no longer than 2 weeks indicate a bacterial 
or viral infection, while longer lasting cases suggest para-
sitic etiology and require specific treatment. Conventional 
methods of diagnostics include microbiological culture for 
bacteria, immunoenzymatic tests for viruses, and micro-
scopic assessment of stool samples for parasites. If these 
methods appear to be insufficient, looking for pathogen’s 
DNa in patient’s blood will deepen the search [2]. However, 
diagnostics can encounter several challenges. For example, 
diarrhoeagenic E. coli shares part of its genetic sequence 
with commensal strains [15]. also, the identification of 
E. histolytica is problematic because it is impossible to dis-
tinguish it microscopically from non-pathogenic E. dispar [9]. 
apart from investigation to discover the pathogen which 
caused the disease, several common tests should also be 
performed, such as full blood count, liver enzymes, renal 
functioning, to assess the overall health of the patient [4].
Treatment. Most cases of travelers’ diarrhea are mild 
and self-limiting and resolve without medical attention [7]. 
Many tourists receive pre-travel advice from their doctors 
and carry a TD kit with them to administer self-treatment 
if necessary. The main objective of self-treatment of a sim-
ple TD, which is not associated with any accompanying 
symptoms, is to compensate the loss of body fluid and to 
soothe the symptoms. easy informal methods of rehydration 
include eating soup and drinking sugar-flavoured water and 
biting on salty crackers. Formal oral rehydration therapy is 
recommended to the most vulnerable groups of patients, 
e.g. infants, young children and the elderly, as well as to 
any patient with cholera-like diarrhea [3]. Diarrhea is not 
a contraindication against eating solid foods as they induce 
the recovery of damaged enterocytes [4]. In more severe 
cases antimicrobials (mentioned below) carried in travel-
er’s kit are to be self-administered by the patient. Despite 
self-treatment being a very common practice, there are 
several situations when medical attention is required. These 
include: lack of improvement after 24 hours of the initial 
onset of symptoms, high fever, severe abdominal pain, 
signs of dehydration, frequent vomiting, which makes it 
impossible to compensate the loss of fluids, blood stains in 
stool or melena, no rapid improvement after self-treatment 
and persistent diarrhea of more than 3–4 days. Severe or 
uncomfortable diarrhea is usually treated by a 3-day empir-
ical course of wide-spectrum-antibiotics [3]. antimicrobial 
treatment shortens the duration of symptoms to a day and 
a half (in comparison with the average of 4 days in cases 
of untreated TD) [8]. The common choice is fluoroquino-
lone (ciprofloxacin, 750 mg once daily for 1 to 3 days) and 
azithromycin (500 mg once daily for 3 days or 1000 mg in 
a single dose) as a second option [3, 8]. However, azithromy-
cin should be considered as the first-line treatment option 
for tourists travelling to Southeast asia for the reason that 
a majority of infections in the region are caused by Campy-
lobacter, which shows 60% resistance to fluoroquinolones 
[1]. rash, photosensitivity and GI complaints are rare side-ef-
fects of using fluoroquinolones. However, fluoroquinolones 
were found to interact with some drugs such as warfarin, 
phenytoin, ciclosporin and theophylline, as well as they are 
not recommended for pregnant women and small children. 
although it acts more slowly than ciprofloxacin in Campy-
lobacter-negative patients, azithromycin does not alter the 
pharmacokinetics of other drugs and is a good alternative 
for children (however, it has not been licensed for use by 
pregnant women). a relatively new antimicrobial is semi-
synthetic rifaximin. The studies have shown that in cases 
of a secretory diarrhea treatment with rifaximin (200 mg 
3 times daily for 3 days) [8] is as effective as with ciproflox-
acin [3]. It is not absorbed through the intestinal wall and 
thus it does not cause any systemic effects [4]. However, 
rifaximin has not been tested on patients presenting with 
diarrhea complicated by fever, systemic toxicity or blood 
stained stools, thus it is not recommended in such cases. 
although antisecretory and antimotility agents, such as 
loperamide, will reduce the passage of stools even by 65%, 
they may have a negative effect on the clinical course of 
diarrhea, especially in cases of an invasive infection; this 
is due to the fact that they cease the evacuation of the 
pathogen through the intestines and they have no direct 
effect on the disease-causing microorganisms [3]. antibiotic 
treatment will note resolve diarrhea of viral etiology. How-
ever, most viral cases are mild and resolve spontaneously 
within 24–72 hours. On suspicion of a parasitic infection, 
persistent diarrhea should be treated with metronidazole, 
which is the treatment of choice in cases caused by Giardia 
intestinalis infection [4]. each case of a diarrhea complicat-
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ed by fever and bloody stools or cholera-like watery diarrhea 
should be further investigated by obtaining and assessing 
blood and stool samples; treatment should be adjusted 
according to test results (Table 3) [22].
PERSISTENT OR REFRACTORY DIARRHEA
Persistent diarrhea accounts for 2% of all TD cases. It 
is defined as diarrhea lasting more than 14 days, although 
in 1% of cases it may persist longer than 4 months. re-
fractory diarrhea is a diarrhea which does not respond to 
antibiotic therapy at all or relapses soon after the comple-
tion of treatment. In such cases multi-resistant bacteria 
or protozoa are usually found to be responsible for the 
infection. The etiology of persistent or refractory diarrhea 
often remains unknown, in spite of a wide range of available 
diagnostic methods. a number of different etiologies, not 
only infectious, should be taken into consideration. Initial 
investigation of persistent diarrhea should include, apart 
from a thorough interview, examination of at least 3 stool 
samples collected on different days, to be examined in the 
light microscopy for the presence of intestinal parasites, and 
for a bacterial culture (especially for Salmonella, Shigella 
and Campylobacter) [8]. Stool should also be examined for 
fecal leukocytes, lactoferrin and occult blood. For as long 
as the results of the above-mentioned tests are awaited, 
the patient should avoid dairy products and should take the 
hydrogen breath test for lactose intolerance if dietary re-
striction was inconclusive. Further investigations include GI 
endoscopy with a biopsy of the small or the large intestine, if 
the symptoms indicate a distal infection. If major symptoms 
still exist and weight loss is progressive, the patient should 
be examined for celiac disease by measuring the serum 
anti-transglutaminase antibodies [10]. Some patients de-
velop symptoms of inflammatory bowel disease after a trip 
to the tropics. Other possible diagnoses include neoplasia 
and endocrinopathy. additionally, some medications could 
be the cause of persistent diarrhea. 
In the absence of a specific etiologic diagnosis, the 
following therapy is suggested:
 — discontinuation of medications which can cause diar-
rhea (e.g. laxatives, antibiotics, diuretics);
 — administration of antimotility agents, such as lopera-
mide; bismuth subsalicylate; probiotics, e.g. Lactoba-
cillus or Saccharomyces, which prevent antibiotic-as-
sociated diarrhea;
 — dietary modification to avoid food which irritates the 
bowel, i.e. alcohol, spicy food, caffeine;
 — cholestyramine resin to bind bile-acids;
 — bulk agents, e.g. psyllium, which increase fecal capacity 
of holding water [10].
Table 3. Travelers’ diarrhea management algorithm
PRE-TRAVEL
Pre-travel advice:
1. Definitions of TD and classification of severity.
2. Importance of oral rehydration through fluid and salt intake for all TD.
3. Information on effectiveness of treatments for TD and the risk of travel, TD and antibiotic use with the acquisition  
of multi-drug resistant bacteria.
4. Provision of empiric treatment medications as indicated by itinerary and practitioner-traveler determination.
5. Intra- and post-travel illness follow-up recommendations.
DURING TRAVEL
Self-determination of illness severity
Mild Moderate Severe
Diarrhea that is tolerable, not distressing, 
does not interfere with planned activities
Diarrhea that is distressing or  
interferes with planned activities
Diarrhea that is incapacitating or prevents planned activities
Non-dysentery Dysentery*
May use loperamide or bismuth subsali-
cylates
May use loperamide alone Or
as an adjunct to antibiotics
May use loperamide  
as an adjunct to antibiotics
+/– +
May use antibiotic Should use antibiotic
POST-TRAVEL
acute TD should be treated empirically as above
Microbiologic testing is recommended in returning travelers with severe or persistent symptoms or in those who fail empiric therapy
Multiplex molecular diagnostics are preferred in patients with persistent or chronic symptoms
*all dysentery is considered severe. Source: riddle M, et al. Guidelines for the prevention and treatment of travelers’ diarrhea: a graded expert panel report. J Travel Med. 
2017; 24(Suppl. 1): S57–S54 [22]; TD — travelers' diarrhea
Int Marit Health 2019; 70, 4: 244–251
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POST-INFECTIOUS IRRITABLE BOWEL  
SYNDROME (PI-IBS)
Post-infectious irritable bowel syndrome is a problem 
affecting 3% to 17% of patients after they had experienced 
TD [8, 23]. when chronic enteric infection and organic GI dis-
ease are excluded, symptoms such as abdominal pain and 
altered bowel movement habits are suggestive of an irritable 
bowel syndrome which has developed after gastroenteritis 
or TD [23, 24]. There are some generally recognised factors 
which are associated with the development of PI-IBS, e.g. 
the severity of TD, the number of TD episodes, the history 
of pre-travel diarrhea or other adverse life events, and the 
etiology factor of TD being a heat-labile toxin-producing eTeC. 
Other risk factors include young age and female gender, as 
well as personality features, e.g. being prone to stress, anxi-
ety, having a high level of neuroticism and somatisation. If TD 
is caused by a bacteria which destroys the intestine wall (e.g. 
Salmonella, Shigella or Campylobacter), the risk of develop-
ing PI-IBS afterwards further increases [24]. Giardiasis often 
imitates the PI-IBS, causing malabsorption and subsequent 
bloating, nausea and vomiting [18]. The results of a pro-
spective cohort study suggest that TD patients treated with 
antibiotics were less likely to develop PI-IBS than patients 
who cured spontaneously [25], although some meta-anal-
yses include antibiotics as a risk factor [24]. More studies 
need to be performed to assess the etiologic factors of PI-IBS 
and in result to define the right treatment strategies [18].
PREVENTION OF GASTROINTESTINAL  
INFECTIONS
Prevention against GI infections should begin well before 
the travel by seeking advice from a family doctor or a special-
ist in travel medicine. This advice should include such topics 
as hand hygiene, choice of safe food and beverages and 
fluid replacement. It should mention the situations when 
seeking professional medical help is crucial. Unfortunately 
only 2% patients comply with the instructions [11].
The common advice to avoid street food is hard to follow 
as trying local cuisine is considered as a part of cultural 
experience [13]. local street food is often described as the 
most delicious by the ones who dared to try it. Therefore, 
the patient should at least remember that freshly prepared 
food which is served steaming hot (at least 70 centigrade 
degrees), peeled or highly citrus fruits and dry foods are 
the safest [11]. Old rule “Cook it, boil it, peel it or forget it” 
still functions well [4].
Many bacteria can be swallowed with a sip of water, 
especially Shigella which has a low infective dose. a trav-
eller should avoid tap water and ice cubes [3, 4], and stick 
to purified bottled water. It is to be remembered that tap 
water is often sold as purified water in bottles in many 
developing countries [3]. Carbonated water is safer to 
drink as it has a lower pH which kills enteropathogenic 
bacteria; there were some cases of diarrhea in Mexico 
and Portugal caused by contaminated noncarbonated 
bottled water. Boiling water for 1 min kills most of the 
bacteria (on high altitudes above 2000 m water should 
be boiled for at least 3 min) [26]. alcohol consumption 
has not been identified as a preventive method nor 
a risk factor of TD [6].
another form of pre-travel prevention is vaccination. 
There are several vaccines recommended for travelers: 
against typhoid fever, viral hepatitis a, and cholera. The 
latter is known in several countries like Canada and Sweden 
as “a travelers’ diarrhea vaccine”, as it gives a partial (7%) 
cross-protection against heat-labile toxin-producing eTeC. 
although its protective efficacy against eTeC lasts 3 months 
only, some patients could benefit from getting vaccinated [4].
although there is an improvement of hygiene status in 
developing countries [11], washing hands with water and 
soap or cleaning them with an antibacterial gel should nev-
er be avoided [4]. Bismuth subsalicylate taken as a preven-
tive medication 4 times a day during travel reduces the risk 
of TD by 65%. Its adverse effects include turning the tongue 
and stools black — the latter should be considered when 
diagnosing bloody stools. Salicylate compounds should be 
avoided by patients who take anticoagulants or salicylate 
on the long term [8]. The use of synbiotics, prebiotics 
and probiotics has not been supported by any study thus 
its use in order to prevent TD is not recommended [13]. 
Chemoprophylaxis is usually not recommended because 
of higher cost than eventual self-treatment, although there 
are four groups of people for which we should propose this 
form of prevention. These include people who take short 
3–5-day trips and cannot be trapped in a hotel room with 
GI symptoms (i.e. sportsmen, businessmen, musicians, 
lecturers), patients who have already experienced TD and 
can be considered as prone to it, immunodeficient patients 
suffering from chronic diseases, aIDS, cancer, heart failure 
or diabetes treated with insulin, and the last group — pa-
tients who have requested for chemoprophylaxis [27]. 
a popular drug is rifaximin, which would prevent 72% of 
infections [4].
CONCLUSIONS
Gastrointestinal disorders remain the most common 
problem among travelers that can ruin every vacation 
or an international business meeting. In most cases the 
symptoms are either self-limiting or disappear after easy 
empirical 3-day antimicrobial treatment. Doctors in home 
countries will encounter either patients with acute diarrhea 
which started at the end of the trip, or persistent diarrhea, 
mostly caused by parasites. Sometimes travel masks the 
real reason of sickness, so non-infectious and post-infec-
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tious diagnoses should also be taken into consideration. 
These include lactose intolerance, celiac disease, neoplasm, 
post-infectious irritable bowel syndrome, and side-effects 
of the medications.
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